All In Biotech

Drug Trial Radar · NCT03992404

Study to Compare the Efficacy and Safety of NT 201 (Botulinum Toxin) With Placebo for the Treatment of Lower Limb Spasticity Caused by Stroke or Traumatic Brain Injury

Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of NT 201 in the Treatment of Lower Limb Spasticity Caused by Stroke or Traumatic Brain Injury in Adult Subjects, Followed by an Open Label Extension With or Without Combined Upper Limb Treatment

Last checked: Nov 20, 2026Latest source record: Oct 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 603 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

603

Actual

Start

Sep 16, 2019

Primary completion

Jun 19, 2025

Study completion Apr 2027

Sponsor

Lead sponsor
Merz Pharmaceuticals GmbHIndustry
Sponsor type
Industry
First posted
Jun 20, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine whether a single treatment with administration of 400 Units NT 201 (botulinum toxin) is superior to placebo (no medicine) for the treatment of lower limb spasticity caused by stroke or traumatic brain injury (Main Period). Participants will be assigned to the treatment groups by chance and neither the participants nor the research staff who interact with them will know the allocation. The following 4 to 5 treatment cycles will investigate the safety and tolerability of treatment with NT 201 (botulinum toxin) when administered in doses between 400 and 800 Units (Open Label Extension Period). All participants will receive the treatment and the dose will depend on whether only lower limb spasticity or combined upper and lower limb spasticity are treated.

Conditions

  • Lower Limb or Combined Lower Limb and Upper Limb Spasticity Due to Stroke or Traumatic Brain Injury

Interventions

  • NT 201Drug

    Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).

  • PlaceboDrug

    Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in derived Modified Ashworth Scale-Bohannon (MAS) ankle score (knee extended) at weeks 4 to 6Time frame: Baseline to week 4-6
  2. Co-Primary: Global Impression of Change Scale (GICS) assessed by physician at Week 4 to 6Time frame: Week 4-6
  3. Occurrence of treatment emergent adverse events [TEAEs] in the Main PeriodTime frame: Baseline to week 12

Locations

71 sites in 15 countries. Site status is shown where the registry gives one.

  • Physical Medicine and Rehabilitation at University of Alabama at Birmingham; Merz investigational site #0010479

    Birmingham, Alabama

  • University of Arkansas for Medical Sciences, Merz investigational site #0010481

    Little Rock, Arkansas

  • Rancho Research Institute at Rancho Los Amigos National Rehabilitation Center; Merz investigational site #0010184

    Downey, California

  • New England institute for clinical research; Merz Investigational Site #0010441

    Stamford, Connecticut

  • Nova Clinical Research, Merz investigational site #0010474

    Brandenton, Florida

  • Brooks Rehabilitation Clinical Integration and Research, Merz investigational site #0010483

    Jacksonville, Florida

  • Sarasota Memorial Health Care System, Rehabilitation Medicine, Merz investigational site #0010478

    Sarasota, Florida

  • Neurology Center of New England P.C., Merz investigative site #0010476

    Foxborough, Massachusetts

  • Howard A. Rusk Rehabilitation Center; Merz investigational site #0010283

    Columbia, Missouri

  • Icahn School of Medicine at Mount Sinai, Neurology Department, Merz Investigational Site #0010191

    New York, New York

  • Weill Cornell Medical Center, Department of Rehabilitation Medicine; Merz Investigational Site #0010440

    New York, New York

  • University of Pittsburgh Medical Center, Physical Medicine & Rehabiliation, Merz Investigational Site #0010211

    Pittsburgh, Pennsylvania

  • UT Southwestern Medical Center, Department of Physical Medicine & Rehabilitation, Merz investigational site #0010082

    Dallas, Texas

  • University of Texas Health Science Center McGovern, Medical School Department of PM&R; merz investigational site #0010183

    Houston, Texas

  • Medical College of Wisconsin,Department of PM&R, Merz Investigational Site #0010237

    Milwaukee, Wisconsin

  • CHU Brugmann Neurology; Merz investigational site #0320015

    Brussels, Belgium

  • UCL Bruxelles, Physical Medicine & Rehabilitation Department, Merz Investigational Site #0320013

    Brussels, Belgium

  • UZ Leuven Pellenberg campus; Merz investigational site #0320014

    Pellenberg, Belgium

  • UCL Mont Godinne, Physical Medicine & Rehabilitation Department; Merz Investigational Site #0320008

    Yvoir, Belgium

  • Glenrose Rehabilitation Hospital, Merz investigational site #0010195

    Edmonton, Canada

  • Neurology and Physiotherapy Skopalikova, Merz Investigational Site #4200049

    Brno, Czechia

  • University Hospital Ostrava; Neurology Departement, Merz investigational site #4200024

    Ostrava, Czechia

  • Pardubice Regional Hospital; Merz investigational site #4200025

    Pardubice, Czechia

  • Raymond Poincaré University Hospital, Service de MPR Pôle Handicap-Rééducation, Merz Investigational site #00330018

    Garches, France

  • CHU Lille/Hôpital Swynghedauw; investigational site # 0330045

    Lille, France

  • Pôle Saint-Hélier; Merz investigational site #0330024

    Rennes, France

  • Institut Universitaire de Readaptation Clemenceau, Physical Medicine / Rehabilitation Medecine, Merz Investigational site # 0330063

    Strasbourg, France

  • Rangueil Hospital-University Hospital Center (CHU) of Toulouse, Médecine physique et de réadaptation, Merz investigational site #0330025

    Toulouse, France

  • Uniklinik RWTH Aachen, Neurologie, Merz Investigational Site #0490191

    Aachen, Germany

  • Neurologie Bewegt; Merz Investigational site #0490378

    Berlin, Germany

  • University of Bonn Medical Center, Department of Neurodegenerative disease, Merz investigational site #0490390

    Bonn, Germany

  • Heinrich Heine University Duesseldorf, Department of Neurology; Merz Investigational Site #0490071

    Düsseldorf, Germany

  • Universitätsklinikum Hamburg-Eppendorf, Merz Investigational site #0490079

    Hamburg, Germany

  • DKD HELIOS Medical Center, Fachbereich Neurologie, Merz Investigational Site #0490081

    Wiesbaden, Germany

  • Neurologische Klinik und Poliklinik des Universitätsklinikums Würzburg, Merz Investigational Site #0490302

    Würzburg, Germany

  • Petz Hospital, Neurology, Merz Investigational Site #0360010

    Győr, Hungary

  • St.Damjan Hospital, Kisvarda; Merz investigational site #0360019

    Kisvárda, Hungary

  • University of Szeged, Department of Neurology, Merz investigational site #0360008

    Szeged, Hungary

  • Azienda Ospedaliera Universitaria Ospedali Riuniti Di Foggia; Merz Investigational Site #0390018

    Foggia, Italy

  • IRCCS Ospedale Policlinico S. Martino, U.O.Complessa Riabilitazione e Rieducazione Funzionale; Merz investigational site #0390020

    Genova, Italy

Showing 40 of 71 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.